---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-008204"
form_type: "8-K"
ticker: "INMB"
cik: "0001711754"
company_name: "Inmune Bio, Inc."
filed_at: "2026-01-27T23:59:59+00:00"
generated_at: "2026-05-16T07:33:43.076826+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# INmune Bio updates on CORDStrom RDEB timing and XPro Alzheimer's Phase 2 results

## Summary
- CORDStrom commercial pilot runs completed; MAA to UK MHRA planned mid-2026; BLA to FDA targeted end of 2026.
- XPro Phase 2 MINDFuL missed primary endpoint in broad population (n=200) but showed cognitive effect (EMACC d=0.27) in biomarker-defined subpopulation (n=100).
- Cash position $27.7M as of Sept 30, 2025, expected to fund operations through year-end 2026.
- XPro reduced pTau217 and neuroimaging suggested reduced neurodegeneration in the subgroup.
- Regulatory timelines for CORDStrom and XPro remain subject to feedback and manufacturing readiness.

## SEC filing metadata
- accession: 0001213900-26-008204
- form_type: 8-K
- ticker: INMB
- cik: 0001711754
- company_name: Inmune Bio, Inc.
- filed_at: 2026-01-27T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1711754/000121390026008204/0001213900-26-008204-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1711754/000121390026008204/ea0274317-8k_inmune.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-008204
- JSON: https://secwatch.observer/filing/0001213900-26-008204.json
- Plain text: https://secwatch.observer/filing/0001213900-26-008204.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.